



CLAIMS

1. A compound which is (*E*)-1-(4-(5-carbamoyl-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-(3-morpholinopropoxy)-1H-benzo[d]imidazole-5-carboxamide having the structure of



- or a tautomer thereof,
or a pharmaceutically acceptable salt thereof,
or a hydrate thereof.
2. The compound according to claim 1, which is a pharmaceutically acceptable salt of (*E*)-1-(4-(5-carbamoyl-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-(3-morpholinopropoxy)-1H-benzo[d]imidazole-5-carboxamide, or a tautomer thereof.
3. The compound according to claim 1, which is (*E*)-1-(4-(5-carbamoyl-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-(3-morpholinopropoxy)-1H-benzo[d]imidazole-5-carboxamide, or a tautomer thereof.
4. The compound according to claim 1, which is represented by (*E*)-1-((*E*)-4-((*E*)-5-carbamoyl-2-((1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)imino)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-((1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)imino)-

7-(3-morpholinopropoxy)-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamide having the structure of



or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising the compound, a tautomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate thereof according to any one of claims 1- 4, and a pharmaceutically acceptable excipient.

6. A compound, a tautomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate thereof according to any one of claims 1- 4 for use in therapy.

~~7. A compound, a tautomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate thereof according to any one of claims 1- 4 for use in the treatment of a STING-mediated disease.~~

~~87. Use of the compound, a tautomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate thereof according to any one of claims 1- 4 in the manufacture of a medicament for the treatment of a STING-mediated disease, wherein the STING-mediated disease is inflammation, an allergic or autoimmune disease, an infectious disease, cancer, or pre-cancerous syndromes.~~

~~98. The compound or use according to any of claims 6-8 7, wherein the disease or disorder is infectious disease.~~

~~109. The compound or use according to any of claims 6-97-8, wherein the disease or disorder is HIV.~~